AstraZeneca succeeds in omeprazole patent infringement profits case
by Urszula Wojtyra
The Federal Court has issued its Public Judgment and Reasons concerning the financial compensation to be paid to AstraZeneca as a result of Apotex’s infringement of the omeprazole formulation patent (AstraZeneca’s LOSEC) in AstraZeneca v Apotex Inc 2017 FC 726.
AstraZeneca elected an accounting of Apotex’s profits after Justice Barnes found the omeprazole formulation patent valid and infringed during the liability phase (reported here). The parties had substantially settled many of the quantification issues relating to Apotex’s profits, leaving four issues for the Court to decide following a 28-day trial – all of which were decided in AstraZeneca’s favour.
AstraZeneca was successfully represented by a trial team from Smart & Biggar, including Nancy Pei, Mark Biernacki, J. Sheldon Hamilton, Urszula Wojtyra, Abigail Smith, Paul Jorgenson and Brandon Heard.
To learn more, click here »
Connect with us:
Smart & Biggar named the 2017 “Canadian IP Litigation Firm of the Year” by Benchmark Canada for the third consecutive year.
Read more »
Smart & Biggar was awarded the Milestone Case of the Year for North America and named Canadian Trademark Contentious Firm of the Year by Managing Intellectual Property.
Read more »